Market Dashboard
- You are here:
- Home
- Markets
- Market Dashboard
- Dr. Reddys Laboratories Ltd.
NSE Symbol: | BSE Code: | ISIN: | Sector:
- Add to Portfolio
- Add to Watchlist
- Add to Alert
- Add to Message
| Change | Change % |
| -55.20 | -1.21% |
Updated:31 May, 2023, 15:58 PM IST |
|
| Change | Change % |
| -54.20 | -1.19% |
Updated:31 May, 2023, 16:01 PM IST |
|
Day's Range
52 Wk Range
Compare Price performance of vs. Peer Companies
From sector
Compare with Peers on Key Fundamentals and Financials
- SUNPHARMA
0.87% - DIVISLAB
-0.78% - CIPLA
-0.15% - DRREDDY
-1.19% - CADILAHC
-1.93% - ABBOTINDIA
-0.75% - ALKEM
0.17% - AUROPHARMA
7.75% - LUPIN
-0.11% - TORNTPHARM
8.15% - BIOCON
1.28% - GLAXO
0.35% - PFIZER
0.39% - JBCHEPHARM
0.09% - GLENMARK
0.57% - SANOFI
-0.24% - PEL
-0.57% - AJANTPHARM
0.89% - NATCOPHARM
-2.31% - APLLTD
-1.27% - ASTRAZEN
9.39% - IPCALAB
1.78% - ERIS
1.09% - MERCK
0.98% - GRANULES
0.27% - CAPLINLABS
1.49% - FDC
0.92% - HIKAL
7.79% - NEULANDLAB
4.74% - LAURUSLABS
-1.20%
's Latest Research Report
| Brokerage/Analyst | Report Date | Call | Price@Call | Target | Current Status | Report |
|---|---|---|---|---|---|---|
| Nomura - |
26-09-2019 | Buy | 2775.25 | 3284.00 | Closed | Details |
| Nomura - |
30-07-2019 | Buy | 2581.50 | 3285.00 | Closed | Details |
| Elara Capital - |
04-02-2019 | Sell | 2805.00 | 2759.00 | Target Hit | Details |
| Edelweiss - |
30-06-2018 | Buy | 2235.05 | 3350.00 | Closed | Details |
| Nomura - |
30-01-2018 | Buy | 2330.00 | 3238.00 | Closed | Details |
More from Research Reports »
Dr. Reddys Lab's Key Fundamentals
| Parameter | Values |
|---|---|
| Market Cap (in ₹ Cr.) | 74,765.59 |
| Earning Per Share (EPS TTM) (₹) | 78.02 |
| Price To Earnings (P/E) Ratio | 57.69 |
| Book Value Per Share (₹) | 706.34 |
| Price To Books (P/B) Ratio | 6.37 |
| EBIT Margin (%) | 8.12 |
| PAT Margin (%) | 6.06 |
| ROCE (%) | 5.36 |
| PAT Growth (%) | -59.04 |
| Total Debt to Equity (D/E) Ratio | 0.22 |
More from Key Fundamentals »
Dr. Reddys Lab's Financial Summary
| Parameter | MAR'18 (₹ Cr.) |
MAR'17 (₹ Cr.) |
YoY %Change |
|---|---|---|---|
| Balance Sheet: | |||
| Share Capital | 83.00 | 82.90 | 0.12% |
| Total Non-Current Liabilities | 479.50 | 506.50 | -5.33% |
| Total Current Liabilities | 4,719.90 | 4,258.00 | 10.85% |
| Total Liabilities | 17,007.20 | 16,365.10 | 3.92% |
| Total Non-Current Assets | 7,968.70 | 7,771.30 | 2.54% |
| Currents Investments | 1,682.80 | 1,299.10 | 29.54% |
| Cash and Bank | 120.70 | 66.80 | 80.69% |
| Total Current Assets Excluding Current Investments | 7,355.70 | 7,294.70 | 0.84% |
| Total Assets | 17,007.20 | 16,365.10 | 3.92% |
| Profit and Loss: | |||
| Gross Sales | 9,359.30 | 9,719.80 | -3.71% |
| Net Sales | 9,359.30 | 9,719.80 | -3.71% |
| PBIDT (Excl OI) | 1,272.60 | 1,678.60 | -24.19% |
| PAT | 566.90 | 1,384.10 | -59.04% |
More from Financial Summary »
Dr. Reddys Lab's Shareholding Pattern
| Description | Percent of Share (%) |
|---|---|
| Promoters | 25.61 |
| Individuals | 8.17 |
| Institutions | 13.43 |
| FII | 27.42 |
| Govt. | 0.00 |
| Others | 25.37 |
More from Holding Pattern »
Dr. Reddys Lab held by Mutual Fund Schemes
More from Mutual Fund Holding »
's Futures and Options Quotes
| Contract Expiry Date |
Type | Current price | Change | Change % | Premium / Discount |
|---|---|---|---|---|---|
| DRREDDY 29-06-2023 |
FUTSTK |
4537.60 | -12.90 | -0.28% | 36.55 |
| DRREDDY 27-07-2023 |
FUTSTK |
4542.85 | 3.90 | 0.09% | 41.80 |
| DRREDDY 31-08-2023 |
FUTSTK |
4544.00 | -33.40 | -0.73% | 42.95 |
More from Futures and Options Quotes »
Dr Reddy's Laboratories is a pharmaceuticals company headquartered in Hyderabad. Dr Reddy's is one of the world's largest manufacturers of APIs (Active Pharmaceuticals Ingredients). Dr Reddy's Laboratories offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's Laboratories' major markets include the US, India, Russia & CIS (Commonwealth of Independent States) countries, and Europe. With Global Generics being its biggest business driver, Dr Reddy's Laboratories offers more than 200 generic drugs. In FY17, Dr Reddy's Laboratories registered a net profit of Rs 1,384 crore over revenue of Rs 9,720 crore. As of September 2017, the promoter group of Dr Reddy's Laboratories held a 26.77 per cent stake in the company with the public holding the remaining 73.23 per cent.
Dr Reddy's Laboratories shares
Dr Reddy's Laboratories shares trade with the symbol DRREDDY on stock exchanges BSE and NSE.
History
Dr Reddy's Laboratories was founded by Dr K Anji Reddy in 1984.
BackgroundNorth America Generics remain the most significant market for Dr Reddy's Laboratories comprising 55 per cent of the global generics topline, according to the company's annual report of 2017. Its revenue from India for FY2017 grew at 9 per cent year-on-year to Rs 2,310 crore.
Registered office
Dr Reddy's Laboratories, 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana-500034